Machine Learning

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

Causal Dynamics Lab’s Cielara Code is outperforming giants by fixing a core flaw: AI agents can write code, but they can’t find where to put it.

Lighthouse Autism Center is opening a new facility, promising to reduce wait times and provide integrated diagnostic and ABA therapy for local families.

As FDA rules on peptides shift, a new AI platform aims to give doctors clarity, separating solid science from speculation in the booming longevity market.

Linea's ZK rollup stack is now Lineth, a new Linux Foundation project. The move signals a major shift towards vendor-neutral governance for Ethereum scaling.

Tunnell Consulting's perfect CMMC score reveals a cost-effective enclave strategy, challenging the belief that compliance must be an expensive overhaul.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

A new wave of AI builds entire enterprise apps, but can it be trusted? WaveMaker's early success suggests its architecture-first approach is the key.

A new partnership moves AI from isolated tasks to integrated workflows, promising to solve the ROI problem that has plagued enterprise adoption.

Beijing has placed AI-powered robots at the core of its national strategy, aiming to reshape global manufacturing and accelerate a new technological race.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

A new national agreement brings QuVa Pharma's AI-powered drug diversion software to thousands of hospitals, promising a high-tech solution to a hidden crisis.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

Commvault showcases its unified, AI-enabled platform at Red Hat Summit, aiming to secure hybrid cloud workloads in a booming container market.

HealthVerity's acquisition of Symphony Health unites clinical and commercial data, promising to shatter industry silos and accelerate medical breakthroughs.